Kiora Pharmaceuticals (KPRX)
(Delayed Data from NSDQ)
$3.15 USD
-0.09 (-2.78%)
Updated Aug 13, 2024 04:00 PM ET
After-Market: $3.15 0.00 (0.00%) 4:50 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Balance Sheet
Fiscal Year End for Kiora Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 2 | 6 | 8 | 1 | 4 |
Receivables | 2 | 1 | 1 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 0 | 0 | 1 | 0 | 0 |
Total Current Assets | 5 | 8 | 9 | 2 | 4 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 9 | 11 | 9 | 13 | 6 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 14 | 19 | 18 | 15 | 10 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 0 | 1 | 0 | 0 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 1 | 2 | 1 | 1 | 1 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 2 | 3 | 2 | 2 | 1 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 1 | 1 | 1 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 5 | 3 | 7 | 5 | 2 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 8 | 7 | 9 | 8 | 3 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 153 | 146 | 134 | 115 | 107 |
Retained Earnings | -147 | -134 | -125 | -108 | -100 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 6 | 11 | 9 | 7 | 7 |
Total Liabilities & Shareholder's Equity | 14 | 19 | 18 | 15 | 10 |
Total Common Equity | 6 | 11 | 9 | 7 | 7 |
Shares Outstanding | 0.80 | 0.10 | 0.00 | 0.00 | 0.00 |
Book Value Per Share | 7.64 | 114.10 | 9.22 | 7.00 | 6.62 |
Fiscal Year End for Kiora Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 28 | 31 | 2 | 5 | 8 |
Receivables | 4 | 2 | 2 | 1 | 1 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 |
Total Current Assets | 32 | 33 | 5 | 7 | 9 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | 9 | 9 | 9 | 9 | 11 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 41 | 42 | 14 | 16 | 20 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | 0 | 0 | 0 | 0 | 0 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | 1 | 1 | 1 | 1 | 1 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 1 | 0 |
Total Current Liabilities | 2 | 2 | 2 | 2 | 2 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 1 | 1 | 1 | 1 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 5 | 5 | 5 | 4 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | 8 | 8 | 8 | 8 | 6 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 169 | 168 | 153 | 153 | 153 |
Retained Earnings | -136 | -134 | -147 | -145 | -139 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 33 | 35 | 6 | 8 | 14 |
Total Liabilities & Shareholder's Equity | 41 | 42 | 14 | 16 | 20 |
Total Common Equity | 33 | 35 | 6 | 8 | 14 |
Shares Outstanding | 2.90 | 2.90 | 0.80 | 0.80 | 0.70 |
Book Value Per Share | 11.41 | 12.03 | 7.64 | 10.13 | 19.49 |